Dries Reynders
Overview
Explore the profile of Dries Reynders including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
713
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zilli T, Dirix P, Heikkila R, Liefhooghe N, Siva S, Gomez-Iturriaga A, et al.
Eur Urol Focus
. 2021 Jan;
7(2):241-244.
PMID: 33386290
Optimal local treatment for nodal oligorecurrent prostate cancer is unknown. The randomized phase 2 PEACE V-STORM trial will explore the best treatment approach in this setting. Early results on the...
12.
De Bleser E, Jereczek-Fossa B, Pasquier D, Zilli T, van As N, Siva S, et al.
Eur Urol
. 2019 Jul;
76(6):732-739.
PMID: 31331782
Background: Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still lacking. Objective: To compare...
13.
Kataoka K, Ysebaert H, Shiozawa M, Reynders D, Ikeda M, Tomita N, et al.
Eur J Surg Oncol
. 2019 Jun;
45(10):1862-1869.
PMID: 31153766
Introduction: Debate persists on the ideal extent of lymphadenectomy for colon cancer (CC). Specifically, it is unknown whether the anatomical location of positive lymph nodes (LN) has any independent prognostic...
14.
Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, et al.
Eur Urol
. 2019 Jan;
75(5):707-711.
PMID: 30665814
Preclinical data indicate that radiotherapy works synergistically with pembrolizumab, but the effect and toxicity of this combination may depend on radiotherapy timing. We conducted a randomized phase 1 trial combining...
15.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, Lambert B, et al.
J Clin Oncol
. 2018 Jun;
36(22):2351-2352.
PMID: 29856691
No abstract available.
16.
Sundahl N, De Wolf K, Kruse V, Meireson A, Reynders D, Goetghebeur E, et al.
Int J Radiat Oncol Biol Phys
. 2018 Feb;
100(4):906-915.
PMID: 29485070
Purpose: To report the results of a phase 1 trial evaluating the safety of the ipilimumab/radiation therapy combination in patients with metastatic melanoma. Patients And Methods: Thirteen patients with metastatic...
17.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al.
J Clin Oncol
. 2017 Dec;
36(5):446-453.
PMID: 29240541
Purpose Retrospective studies suggest that metastasis-directed therapy (MDT) for oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to assess the benefit of MDT in a randomized phase II trial....
18.
De Grande L, Van Uytfanghe K, Reynders D, Das B, Faix J, MacKenzie F, et al.
Clin Chem
. 2017 Jul;
63(10):1642-1652.
PMID: 28720678
Background: The IFCC Committee for Standardization of Thyroid Function Tests intended to standardize free thyroxine (FT) immunoassays. We developed a Système International d'Unités traceable conventional reference measurement procedure (RMP) based...
19.
Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, et al.
J Transl Med
. 2017 Jul;
15(1):150.
PMID: 28662677
Background: Current first-line standard of therapy for metastatic urothelial carcinoma is platinum-based combination chemotherapy. Pembrolizumab in phase III has demonstrated a promising overall response rate of 21.1% in patients with...
20.
Thienpont L, Van Uytfanghe K, De Grande L, Reynders D, Das B, Faix J, et al.
Clin Chem
. 2017 May;
63(7):1248-1260.
PMID: 28522444
Background: The IFCC Committee for Standardization of Thyroid Function Tests developed a global harmonization approach for thyroid-stimulating hormone measurements. It is based on a multiassay method comparison study with clinical...